| Ticker Details |
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.
|
| IPO Date: |
May 22, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$199.81M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.95 | 3.81%
|
| Avg Daily Range (30 D): |
$0.27 | 3.19%
|
| Avg Daily Range (90 D): |
$0.21 | 2.69%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.27M |
| Avg Daily Volume (30 D): |
.36M |
| Avg Daily Volume (90 D): |
.42M |
| Trade Size |
| Avg Trade Size (Sh.): |
65 |
| Avg Trade Size (Sh.) (30 D): |
54 |
| Avg Trade Size (Sh.) (90 D): |
60 |
| Institutional Trades |
| Total Institutional Trades: |
2,096 |
| Avg Institutional Trade: |
$2.04M |
| Avg Institutional Trade (30 D): |
$1.12M |
| Avg Institutional Trade (90 D): |
$.7M |
| Avg Institutional Trade Volume: |
.07M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.28M |
| Avg Closing Trade (30 D): |
$1.12M |
| Avg Closing Trade (90 D): |
$.81M |
| Avg Closing Volume: |
79.33K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-2.83
|
$-.95
|
$-1.05
|
|
Diluted EPS
|
$-2.83
|
$-.95
|
$-1.05
|
|
Revenue
|
$54.71M
|
$2.06M
|
$7.2M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-78.67M
|
$-26.96M
|
$-29.08M
|
|
Operating Income / Loss
|
$-88.37M
|
$-28.93M
|
$-31.31M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$-60.43M
|
$-19.39M
|
$-4.45M
|
|
PE Ratio
|
|
|
|
|
|
|